Phase Ib/II study of nivolumab combined with palliative radiation therapy for bone metastasis in patients with HER2-negative metastatic breast cancer - Scientific Reports
Source : https://www.nature.com/articles/s41598-022-27048-3
Radiation therapy (RT) can enhance the abscopal effect of immune checkpoint blockade. This phase I/II study investigated the efficacy and safety of nivolumab plus RT in HER2-negative metastatic breast cancer...
Conclusions: The combination of palliative RT for bone metastasis with nivolumab was safe and showed modest anti-tumor activity in cohort A, but not in cohort B. Further investigations regarding the optimal dose and schedule of the combination of RT and ICB, the optimal RT treatment site, the addition of other molecular targeted therapies such...
-
Albert Dekker3yrit is open to interpretation
Incidence of and risk factors for non-hematologic toxicity with combined radiotherapy and CDK4/6 inhibitors in metastatic breast cancer using dose-volume parameters analysis: a multicenter cohort study - Breast Cancer
Source : https://link.springer.com/article/10.1007/s12282-022-01422-5
Background There is a lack of data on combined radiotherapy (RT) and cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) risk factors and toxicity. This study aimed to assess the incidence...
Conclusions: Moderate toxicities are frequent with combined RT and CDK4/6i. Caution is necessary concerning the combined RT and CDK4/6i. Particularly, reducing the dose to normal organs is necessary for combined RT and CDK4/6i.
-
Albert Dekker3yrradiation people don't like them with radiation
What's new in breast cancer research? SABCS 2022 delivers plenty
Lead author Dawn Hershman, MD, of Columbia University Medical Center in New York, and SWOG researchers, including Fred Hutch's Unger and Barlow, also dug into data to see which elderly...
Conclusions: Studies highlight research on treatment toxicity, disparities in insurance, gaps in metastatic care, new therapies and more.
-
Albert Dekker3yrit is potentially useful
Panelists examine key clinical controversies in breast cancer - SABCS Meeting News
Source : https://www.sabcsmeetingnews.org/panelists-examine-key-clinical-controversies-in-breast-cancer/
SABCS has long recognized that open discussion of controversial topics is an integral part of improving clinical practice. The Clinical Controversies session at SABCS on Wednesday, December 7, explored evolving...
Conclusions: Panelists examine key clinical controversies in breast cancer.
-
Albert Dekker3yrmy hormonal therapy is 7 to 10 years
View from the Trenches: Panel reviews practice-changing presentations from SABCS 2022 - SABCS Meeting News
Following 4 days of non-stop data and practice-changing sessions, a panel of experts reviewed some of the ways they expect information presented at SABCS 2022 to adjust practice and make...
Conclusions: Following 4 days of non-stop data and practice-changing sessions, a panel of experts reviewed some of the ways they expect information presented at SABCS 2022 to adjust practice and make an immediate impact in the clinic during the View from the Trenches: What to do on Monday Morning? session on Friday, December 9.
-
Albert Dekker3yrnothing is really new